The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why

Simply Wall St.05-20

CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636828748?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-05-20 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636828748","market":"us","top_or_hot":-1,"title":"The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why","media":"Simply Wall St.","content":"<div>\n<p>CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-20 21:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian","article_id":"2636828748","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/the-bull-case-for-csl-asxcsl-could-change-following-canadian","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636828748","pubTimestamp":1779284704,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in Ontario and British Columbia while other provinces review coverage.\nThis early real-world use of HEMGENIX® under public funding in Canada highlights how CSL’s high-value gene therapy portfolio is beginning to translate into tangible patient access and market uptake.\nNext, we’ll examine how this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK7508":"医药生物股","AGIX":"通用人工智能 ETF-AGIX","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4587":"ChatGPT概念","BK4528":"SaaS概念","BK4086":"建筑产品","BK7511":"ESG概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4588":"碎股","AI":"C3.ai, Inc.","BK7067":"生物科技","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK7501":"新冠治疗股","BK4551":"寇图资本持仓","AIPO":"Defiance AI and Power Infrastructure ETF","BK4585":"ETF&股票定投概念","BK4023":"应用软件","BK4543":"AI","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"加拿大HEMGENIX报销里程碑后，CSL(ASX：CSL)的牛市可能会发生变化-了解原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5,"ARTY":0.71,"AGIX":0.71,"AIYY":0.6,"AI":0.71,"AIPO":0.82,"CHAT":0.71},"content_text":"CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in Ontario and British Columbia while other provinces review coverage. This early real-world use of HEMGENIX® under public funding in Canada highlights how CSL’s high-value gene therapy portfolio is beginning to translate into tangible patient access and market uptake. Next, we’ll examine how this expansion of publicly reimbursed access to HEMGENIX® in Canada may influence CSL’s broader investment narrative. The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.AdvertisementCSL Investment Narrative RecapTo own CSL today, you need to believe in its ability to turn high-cost plasma and specialty R&D into durable, high-return therapies while managing margin pressure and elevated debt. The first publicly funded HEMGENIX treatment in Canada supports the case that newer products can gain real-world traction, but the key near term catalyst remains broader uptake of recent launches, and the biggest risk is still slower-than-hoped adoption that leaves margins and earnings under pressure. This news looks helpful, but not yet transformational on its own. Against that backdrop, CSL’s updated FY2026 revenue guidance of around US$15.2 billion is the most relevant recent announcement, because it frames how much room the company has to absorb high development and commercialization costs while newer therapies like HEMGENIX ramp. Investors watching early Canadian gene therapy uptake will likely be weighing it against this guidance, especially after a year marked by a large one off loss and a sharp drop in reported earnings. Yet even as HEMGENIX access expands, investors should be aware that slower than expected adoption of new launches could still... Read the full narrative on CSL (it's free!)CSL's narrative projects $17.8 billion revenue and $3.7 billion earnings by 2029.Uncover how CSL's forecasts yield a A$195.41 fair value, a 98% upside to its current price.Exploring Other PerspectivesASX:CSL 1-Year Stock Price Chart Some of the lowest analyst estimates assumed revenue of about US$16.9 billion and earnings of US$3.7 billion by 2029, which is a far more cautious view than the consensus and may understate how events like HEMGENIX’s funded use could shift the story.Explore 13 other fair value estimates on CSL - why the stock might be worth over 2x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.Searching For A Fresh Perspective?Our daily scans reveal stocks with breakout potential. Don't miss this chance:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Uncover the next big thing with 60 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 43 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636828748","isCrawlerRequest":true}